New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE’s impact on COPD exacerbations in patients with a broad range of eosinophil levels
Importantly, in patients with BEC ≥150 cells/µL, tezepelumab led to a nominally significant reduction of 37% in the rate of moderate or severe exacerbations compared to placebo.1 Studies suggest that approximately 65% of bio-eligible patients with COPD have a BEC greater than or equal to 150 cells/μL.2 In patients with BEC ≥300 cells/µL tezepelumab led to a numerical reduction of 46% in the rate of moderate or severe exacerbations.1 (Table 1.)
Dr
A subgroup analysis of the COURSE trial also showed treatment with tezepelumab resulted in numerical improvements in lung function as measured by forced expiratory volume (FEV1) (improvement of 63mL and 146mL in BEC ≥150 and ≥300 cells/μL respectively, compared to placebo) and in quality of life as measured by the St. George’s Respiratory Questionnaire (SGRQ) score (reduction of 4.2 points and 9.5 points in BEC ≥150 and ≥300 cells/μL respectively).1 The safety and tolerability profile for tezepelumab was consistent with its approved severe asthma indication; the most frequently reported (>10%) adverse events for tezepelumab were worsening of COPD (12.1%) and incidents of COVID-19 infections (14.5%) (this trial commenced in July 2019).1 (Table 2.)
COURSE Phase IIa analysis:
Table 1: Tezepelumab impact on COPD exacerbations versus placebo over 52 weeks1
|
Reduction in exacerbations compared to placebo |
Annualized rate of exacerbations |
Moderate or severe exacerbations |
||
Overall population (n=333) |
17% (90% CI: -6, 36) |
1.75 in tezepelumab group versus 2.11 in placebo group |
BEC less than 150 cells/μL (n=137) |
-19% (95% CI: -90, 25) |
2.04 in tezepelumab group versus 1.71 in placebo group |
BEC greater than or equal to 150 cells/μL (n=196) |
37% (95% CI: 7, 57)
|
1.52 in tezepelumab group versus 2.40 in placebo group |
BEC greater than or equal to 300 cells/μL (n=56) |
46% (95% CI: -15, 75)
|
1.20 in tezepelumab group versus 2.24 in placebo group |
Severe exacerbations |
||
Overall population (n=333) |
48% (95% CI: -11, 76)
|
0.13 in tezepelumab group versus 0.25 in placebo group |
Table 2: Tezepelumab impact on quality of life and lung function versus placebo over 52 weeks1
|
Lung function as measured by pre-bronchodilator forced expiratory volume (FEV1, µL) |
Quality of life improvement as measured by St. George’s Respiratory Questionnaire (SGRQ) score |
||||
Tezepelumab (n)/LS Mean |
Placebo (n)/LS Mean |
LS mean difference (95% CI) |
Tezepelumab (n)/LS Mean |
Placebo (n)/LS Mean |
LS mean difference (95% CI) |
|
BEC less than 150 cells/μL |
73/-0.002 |
63/-0.053 |
0.051 (-0.012,0.114) |
69/-1.91 |
60/-0.30 |
-1.62 (-6.69, 3.45) |
BEC greater than or equal to 150 cells/μL |
90/0.049 |
103/-0.014 |
0.063 (0.009, 0.116) |
88/-7.08 |
96/-2.85 |
-4.23 (-8.51, 0.06) |
BEC counts greater than or equal to 300 cells/μL |
24/0.160 |
31/0.013 |
0.146 (0.044, 0.248) |
22/-10.22 |
27/-0.68 |
-9.53 (-18.11, -0.96) |
INDICATIONS AND LIMITATIONS OF USE / ISI
TEZSPIRE® (tezepelumab)
CONTRAINDICATIONS
Known hypersensitivity to tezepelumab-ekko or excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.
Acute Asthma Symptoms or Deteriorating Disease
TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
Abrupt Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection
It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
Live Attenuated Vaccines
The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥3%) are pharyngitis, arthralgia, and back pain.
USE IN SPECIFIC POPULATIONS
There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.
INDICATION
TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.
Please see full Prescribing Information , including Patient Information and Instructions for Use .
You may
report side effects related to
Notes
COURSE Phase IIa trial
COURSE was a Phase IIa multicentre, randomized, double-blind, placebo-controlled, parallel group trial designed to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving triple inhaled maintenance therapy, and having had two or more documented COPD exacerbations in the 12 months prior to Visit 1. A total of 337 patients were randomized globally, with patients stratified by region and prior number of exacerbations (two vs. three or more). Patients received tezepelumab 420 mg, or placebo, administered via subcutaneous injection at the trial site every four weeks over a 52-week treatment period. The trial included a post-treatment follow-up period of 12 weeks.1,3
Chronic Obstructive Pulmonary Disease (COPD)
COPD refers to a group of lung diseases, including chronic bronchitis and emphysema, that cause airflow blockage and breathing-related problems.4 COPD is the third leading cause of death due to chronic disease and the sixth leading cause of mortality in
The lungs and heart are fundamentally linked and work together.7 COPD mechanisms elevate the risk of both lung and heart events, including severe or even fatal COPD exacerbations and cardiac events, known as cardiopulmonary risk.8-11 Approximately 1 in 5 patients with COPD will die within a year of their first hospitalization for an exacerbation, and pulmonary and cardiac events are a key driver of mortality and the most common reasons for death in patients with COPD.8,12-14
TEZSPIRE
TEZSPIRE(tezepelumab) is being developed by
Amgen collaboration
In 2020, Amgen and
In addition, we are also collaborating with
Respiratory & Immunology
Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
With common pathways and underlying disease drivers across respiratory and immunology,
About
References
-
Singh D, et al. Tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD): efficacy and safety from the phase 2a COURSE study.
American Thoracic Society (ATS) 2024.May 2024 . - Data on File REF-228444 – Blood Eosinophil Count in 65% COPD patients.
-
Clinicaltrials.gov. Tezepelumab COPD Exacerbation Study (COURSE) [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT04039113. [Last accessed:
May 2024 ]. -
GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2023. [Online]. Available at: http://goldcopd.org. [Last accessed:
May 2024 ]. -
Centers for Disease Control and Prevention (CDC ). Leading Causes of Death.United States :CDC ;January 17, 2024 , https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. [Last accessed:May 2024 ]. -
National Heart, Lung, and
Blood Institute (NIH). Learn More Breathe Better:United States :NIH . https://www.nhlbi.nih.gov/BreatheBetter. [Last accessed:May 2024 ]. -
American Lung Association . Your Heart and Lungs: The Ultimate Relationship (2023) Available at: https://www.lung.org/blog/heart-lung-relationship. [Last accessed:May 2024 ]. - Ho TW, Tsai YJ, Ruan SY, et al. In-Hospital and One-Year Mortality and Their Predictors in Patients Hospitalized for First-Ever Chronic Obstructive Pulmonary Disease Exacerbations: A Nationwide Population-Based Study. PLOS ONE. 2014; 9 (12): e114866.
- Donaldson GC et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091-1097;9-2029.
- Watz H et al. Spirometric changes during exacerbations of COPD: A post hoc analysis of the WISDOM trial. Respir Res. 2018;19(1):251.
- Suissa S et al. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957-963.
- Lindenauer PK, Dharmarajan K, Qin L, et al. Risk Trajectories of Readmission and Death in the First Year After Hospitalization for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Apr 15;197(8):1009-1017.
- García-Sanz MT, Cánive-Gómez JC, Senín-Rial L, et al. One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease. J Thorac Dis. 2017; 9 (3): 636‐645. doi:10.21037/jtd.2017.03.34.
- Mannino DM et al. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100: pp.115-122.
-
Corren J, et al. Tezepelumab in adults with uncontrolled asthma [supplementary appendix; updated
April 18 , 2019]. N Engl J Med. 2017;377:936-946. - Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol. 2018;9:1595.
-
AstraZeneca plc . Tezspire (tezepelumab) approved in the US for severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html. [Last accessed:May 2024 ]. -
AstraZeneca plc . Tezspire approved in the EU for the treatment of severe asthma. 2022. Available at: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma.html. [Last accessed:May 2024 ]. -
AstraZeneca plc . Tezspire approved inJapan for the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html. [Last accessed:May 2024 ].
View source version on businesswire.com: https://www.businesswire.com/news/home/20240519716817/en/
Media Inquiries
US Media Mailbox: usmediateam@astrazeneca.com
Source: